Cargando…
SCD1 Confers Temozolomide Resistance to Human Glioma Cells via the Akt/GSK3β/β-Catenin Signaling Axis
Resistance to temozolomide (TMZ), the standard chemotherapy agent for glioblastoma (GBM), poses a major clinical challenge to GBM prognosis. Understanding the mechanisms of TMZ resistance can help to identify novel drug targets and more effective therapies. Recent studies suggest that bioenergetic a...
Autores principales: | Dai, Shuang, Yan, Yuanliang, Xu, Zhijie, Zeng, Shuangshuang, Qian, Long, Huo, Lei, Li, Xuejun, Sun, Lunquan, Gong, Zhicheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758607/ https://www.ncbi.nlm.nih.gov/pubmed/29354058 http://dx.doi.org/10.3389/fphar.2017.00960 |
Ejemplares similares
-
Corrigendum: SCD1 Confers Temozolomide Resistance to Human Glioma Cells Via the Akt/GSK3β/β-Catenin Signaling Axis
por: Dai, Shuang, et al.
Publicado: (2019) -
Targeting autophagy to sensitive glioma to temozolomide treatment
por: Yan, Yuanliang, et al.
Publicado: (2016) -
Novel Function of lncRNA ADAMTS9-AS2 in Promoting Temozolomide Resistance in Glioblastoma via Upregulating the FUS/MDM2 Ubiquitination Axis
por: Yan, Yuanliang, et al.
Publicado: (2019) -
An Insight into the Increasing Role of LncRNAs in the Pathogenesis of Gliomas
por: Yan, Yuanliang, et al.
Publicado: (2017) -
PCDH8 inhibits glioma cell proliferation by negatively regulating the AKT/GSK3β/β-catenin signaling pathway
por: Zong, Zhenkun, et al.
Publicado: (2017)